According to Report Study, the Plasma Protein Therapeutics Market size was accounted at US$ 24.38 billion in 2021 and is expected to reach US$ 52.15 billion by 2030 with a CAGR of 7.6% from 2022 to 2030.
According to Report Study, the Plasma Protein Therapeutics Market size was accounted at US$ 24.38 billion in 2021 and is expected to reach US$ 52.15 billion by 2030 with a CAGR of 7.6% from 2022 to 2030.
Report Highlights
- In 2021, immunoglobulin captured the leading position with more than 45.42% market share.
- The albumin segment is expected to gain significant share over the forecast period.
- The PID segment captured the largest market share in 2020 and is expected to exhibit substantial growth through the forecast period.
- Approximately 70.26% of the market is concentrated in North America and Europe.
- The U.S. spearheaded the market with more than 40.47% share in 2021.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/35593
Growing Investment in Innovation, Rising Demand for Immunoglobulin (IG), Rising Indications and Therapeutic use of Plasma Derived Protein Therapeutics are projected to drive the plasma protein therapeutics market.
Growing Investment in Innovation, Rising Demand for Immunoglobulin (IG) and Rising Indications and Therapeutic use of Plasma Derived Protein Therapeutics to Drive Market
- The plasma protein industry has been investing in research and development of new plasma proteins therapies (e.g.: Ceruloplasmin, IgA, Plasmin) leading to innovative treatments for the benefits of patients. In March 2016, Grifols announced that it will invest US$ 360 Mn to expand its production capabilities for plasma-derived therapies. The investment will increase the plasma fractionation capacity and purification of several proteins. Thus this factors drive the growing investment in innovation.
- Plasma-derived IG is used for a wide range of autoimmune and inflammatory diseases. Increased recognition and treatment of immune deficiencies in developing world have added to the global demand for IG. However, increased use of high dose therapy, particularly in autoimmune neurologic diseases is the major reason for the continued strong growth in demand for IG products. Thus this factors drive the demand for immunoglobulin.
- Plasma protein therapies are used in the treatment of rare diseases. The therapies include: Immunoglobulin’s used to treat a number of diseases in individuals with immune deficiencies and autoimmune diseases, Clotting-factor therapies used for individuals with hemophilia A and B and other bleeding disorders, Albumin, which is used in acute settings to treat individuals with shock, trauma, burns and other conditions. Thus this factors drive the plasma protein therapeutics and their uses.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/35593
Product Insights
Based on product, the plasma protein therapeutics market is segmented into albumin, Immunoglobulins (IG), plasma-derived factor VIII, and others. In 2021, immunoglobulin captured the leading position with more than 45.42% market share. The large share can be attributed to the approval of biologics across multiple indications, ease of administration, and treatment cost.
The albumin segment is expected to gain significant share over the forecast period driven by improved diagnosis of hypoalbuminemia caused by liver cirrhosis and hepatitis B. High demand and usage in China, which is the largest market for albumin, is anticipated to further fuel the growth. Patients suffering from moderate to severe hemophilia A require clotting factor VIII as a preventive or on-demand therapy. However, approximately 70.0% of hemophilia patients receive none or inadequate treatment. The factor VIII market is expected to witness a decline in sales due to increasing competition from recombinant and other long-term therapies.
The others segment includes alpha-1 antitrypsin, hyperimmune immunoglobulins, coagulation factors, fibrogammin, and c1 esterase inhibitors. Alpha-1 Antitrypsin (AAT) is used as a replacement therapy to treat a rare form of hereditary emphysema. The deficiency causes conditions such as Chronic Obstructive Pulmonary Disease (COPD), bronchitis, and neonatal hepatitis. Currently, only about 10.0% to 15.0% of AAT deficient patients receive treatment in the U.S. and Europe, thus creating room for market growth. The overall segment is anticipated to exhibit lucrative growth driven by improvement in diagnosis rate and product launches.
Application Insights
On basis of application, the market for plasma protein therapeutics is segmented into Hemophilia, Primary Immunodeficiency Diseases (PID), Idiopathic Thrombocytopenic Purpura (ITP), and others. Primary immunodeficiency diseases include more than 200 rare, chronic diseases that result from a defect in the immune system.
Globally, more than 6.0 million individuals are living with a PID, of which less than 60,000 cases are reported annually. The PID segment captured the largest market share in 2020 and is expected to exhibit substantial growth through the forecast period. Increasing expansion of clinical applications for immunoglobulins, approval of SCIGs, and high treatment costs are contributing to the segment growth.
Regional Insights
Geographically, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Approximately 70.26% of the market is concentrated in North America and Europe. The U.S. spearheaded the market with more than 40.47% share in 2021. Presence of large patient base, growing geriatric population, availability of well-developed infrastructure for storing, and maintaining high-quality source plasma are some of the key regional drivers. Increased adoption of novel therapeutics and rising disease prevalence are some of the other key factors contributing to the regional growth.
Competitive Landscape
- The Plasma Protein Therapeutics Market is fragmented in terms of number of players. Key players in the global market include Baxter International, Biotest, CSL Behring, GRIFOLS, S.A., Kedrion, Octapharma USA, Inc., Shire Plc., China Biologics and among others
Market Segmentation:
By Product Type
-
- Immunoglobulin
- Albumin
- Coagulation Factor
- C1-esterase inhibitors
- Others
By Application
-
- Hemophilia
- “Primary Immunodeficiency
- Disorder (PID)”
- “Idiopathic Thrombocytopenic
- Purpura”
- Secondary Immunodeficiency
- Hereditary Angioedema
- Other applications
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/35593
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333